AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 20978028
Drug: QVA149 (indacaterol/NVA237)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: QVA149 (indacaterol/NVA237) 300/50 μg
Trial: 18617080
Drug: Behavioral intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Behavioral intervention (20 weekly group sessions encouraging calorie restriction, moderate-intensity physical activity, and the DASH dietary pattern)
Trial: 1655219
Drug: Chemotherapy plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy plus involved-field radiation therapy (24 patients)
Trial: 1655219
Drug: Chemotherapy alone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy alone (24 patients)
Trial: 30725289
Drug: Magnetic steering
RxNorm normalized name: MAGNESIA
DrugBank: Magnesium oxide (DB01377)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Magnetic steering of capsule endoscopy
Trial: 19214661
Drug: Prokinetic agent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prokinetic agent (mosapride 15 mg, orally three times daily) for 4 weeks
Trial: 11445849
Drug: Tegafur (FT)
RxNorm normalized name: tegafur
DrugBank: Tegafur (DB09256)
FDA approved: no
EMA approved: yes
PMDA approved: no
Description: Tegafur (FT) alone or FT plus low doses of cisplatin
Trial: 11360524
Drug: Inhaled beclomethasone
RxNorm normalized name: beclomethasone Inhalant Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled beclomethasone dipropionate (BDP) 1000 micrograms daily for 6 weeks
Trial: 3045746
Drug: Cimetidine (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cimetidine (1 g daily, 3 tablets during the day and 2 tablets at night)
Trial: 26394270
Drug: Glatiramer acetate
RxNorm normalized name: Glatiramer Acetate
DrugBank: Glatiramer (DB05259)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Glatiramer acetate 40 mg/mL three times weekly subcutaneous injection (GA40)
Trial: 21559038
Drug: 10 g/d
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 g/d BSP (n=21)
Trial: 21559038
Drug: 5 g/d
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 g/d BSP (n=22)
Trial: 17964616
Drug: Whey protein
RxNorm normalized name: Whey protein
DrugBank: Whey (DB18685)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Whey protein preload (300 mL, 1 MJ)
Trial: 14668455
Drug: Three-drug regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Three-drug regimen containing efavirenz combined with zidovudine and lamivudine
Trial: 10710885
Drug: Intraglobin (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intraglobin (400 mg/kg/d x 5)
Trial: 10710885
Drug: Venoglobulin-I (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Venoglobulin-I (1 g/kg/d x 2)
Trial: 8726950
Drug: Inhaled glucocorticosteroids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled glucocorticosteroids (standard pediatric doses)
Trial: 1340901
Drug: Subcutaneous Continuous
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous Continuous Preprogrammed Insulin Infusion (SCII)
Trial: 1340901
Drug: Multiple Conventional
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multiple Conventional Insulin Injections (MCII)
Trial: 6502211
Drug: Naloxone (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naloxone (2 mg, i.v.)
Trial: 29890270
Drug: MCC (60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MCC (60 mL·d‐1)
Trial: 25333925
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of OECs and SCs
Trial: 19889796
Drug: Ketoconazole (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketoconazole (200 mg b.i.d.)
Trial: 19889796
Drug: Fluconazole (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluconazole (400 mg once a day)
Trial: 16437366
Drug: Intraoperative peritoneal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intraoperative peritoneal hyperthermic chemotherapy (IPHC)
Trial: 10384736
Drug: Understanding of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Understanding of materials requiring attribution of mental states (e.g. ignorance, false belief)
Trial: 1648488
Drug: 20 mg
RxNorm normalized name: urea 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg isosorbide-5-mononitrate (ISMN)
Trial: 6583715
Drug: Des-Tyr-gamma-endorphin (DT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Des-Tyr-gamma-endorphin (DT gamma E) 1 mg, i.m., for 8 consecutive days
Trial: 27703328
Drug: 5 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg intrathecal pethidine (P5 group)
Trial: 27703328
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg intrathecal pethidine (P10 group)
Trial: 27703328
Drug: Standard group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard group (S group) with 0.5 mL of 0.9% saline
Trial: 18632147
Drug: Abatacept (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Abatacept (10 mg/kg intravenously at 28-day intervals for 6 months)
Trial: 18632147
Drug: Placebo (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (10 mg/kg at 28-day intervals for 6 months)
Trial: 15924546
Drug: Oral antibiotics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral antibiotics given prior to delivery
Trial: 2499342
Drug: GTN spray
RxNorm normalized name: GTN
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GTN spray (Nitro‐Corangin Spray)
Trial: 2499342
Drug: Another GTN
RxNorm normalized name: GTN
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Another GTN Spray
Trial: 28007678
Drug: ERA+probiotic (Bifidobacterium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ERA+probiotic (Bifidobacterium animalis subsp. lactis B94, 1 capsule/day)
Trial: 28007678
Drug: ERA+placebo (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ERA+placebo (1 capsule/day)
Trial: 28007678
Drug: ERA-only (no
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ERA-only (no additional treatments)
Trial: 19474651
Drug: Atazanavir/ritonavir (ATV/r)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atazanavir/ritonavir (ATV/r) 300 mg and ritonavir 100 mg daily for 6 months
Trial: 15470330
Drug: Fluconazole (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluconazole (200 mg daily)
Trial: 8489563
Drug: 1000 mg/day
RxNorm normalized name: RibaTab 1000 MG/day Compliance Pack
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1000 mg/day HR
Trial: 8489563
Drug: 500 mg/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500 mg/day HR
Trial: 2881132
Drug: Penicillin (10(6)
RxNorm normalized name: Penicillin V
DrugBank: Meticillin (DB01603)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Penicillin (10(6) IU three times daily for 6 days)
Trial: 19463347
Drug: Percutaneous coronary
RxNorm normalized name: Glebionis coronaria whole extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Percutaneous coronary intervention plus medical therapy (PCI+MT)
Trial: 19463347
Drug: Initial medical
RxNorm normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Initial medical therapy only (MT)
Trial: 16627442
Drug: Single oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single oral bolus propafenone (600 mg)
Trial: 16627442
Drug: No oral
RxNorm normalized name: Beano Oral Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No oral bolus therapy (no bolus)
Trial: 16627442
Drug: Single oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single oral bolus placebo
Trial: 8434380
Drug: Standard therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard therapy without diltiazem (ND)
Trial: 3319120
Drug: L‐DOPA/carbidopa (Sinemet)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L‐DOPA/carbidopa (Sinemet)
Trial: 23153177
Drug: Liraglutide added
RxNorm normalized name: Liraglutide
DrugBank: Liraglutide (DB06655)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Liraglutide added to insulin therapy
Trial: 23153177
Drug: Insulin dose-increase
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Insulin dose-increase
Trial: 18729731
Drug: Combined folic
RxNorm normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Combined folic acid and B-vitamin therapy
Trial: 12518724
Drug: Photodynamic therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Photodynamic therapy with antioxidants (vitamin E 200 mg/d and polyunsaturated fatty acids 1,000 mg/d)
Trial: 12518724
Drug: Photodynamic therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Photodynamic therapy only (no antioxidants)
Trial: 12518724
Drug: Photodynamic therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Photodynamic therapy with antioxidants
Trial: 12518724
Drug: Photodynamic therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Photodynamic therapy only
Trial: 8172090
Drug: 10 g/d
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 g/d fiber supplement
Trial: 8172090
Drug: 20 g/d
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 g/d fiber supplement
Trial: 23924679
Drug: 4 ×
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 × 25-mg non-coated tablets
Trial: 23924679
Drug: 100-mg tablet
RxNorm normalized name: dapsone
DrugBank: Dapsone (DB00250)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 100-mg tablet dispersed in 100 ml water
Trial: 23924679
Drug: 200-mg non-coated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200-mg non-coated and coated tablets
Trial: 23924679
Drug: 100-mg tablets
RxNorm normalized name: dapsone
DrugBank: Dapsone (DB00250)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 100-mg tablets
Trial: 16487836
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of captopril and valsartan
Trial: 10767065
Drug: Three-dimensional contrast-enhanced
RxNorm normalized name: three-lobe sage extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Three-dimensional contrast-enhanced moving-bed infusion-tracking (MoBI-track) peripheral MR angiography
Trial: 1737593
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of clinical and mammographic measurements
Trial: 6378516
Drug: Prostaglandin treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prostaglandin treatment at home (9‐deoxo‐16, 16‐dimethyl‐9‐methylene‐PGE2, 50 to 60 mg twice at 6‐hour intervals)
Trial: 6378516
Drug: Prostaglandin treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prostaglandin treatment in hospital (9‐deoxo‐16, 16‐dimethyl‐9‐methylene‐PGE2, 50 to 60 mg twice at 6‐hour intervals)
Trial: 29073780
Drug: CWI with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CWI with ropivacaine 2 mg/mL at a rate of 2 mL/h for 24 hours
Trial: 23012417
Drug: Dynamic reconfiguration
RxNorm normalized name: water
DrugBank: Water (DB09145)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dynamic reconfiguration of brain network during task preparation
Trial: 20974610
Drug: Riboflavin 50
RxNorm normalized name: riboflavin 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Riboflavin 50 mg/day
Trial: 17949466
Drug: Nicotine (low
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nicotine (low dose 7 mg)
Trial: 17949466
Drug: Nicotine (high
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nicotine (high dose 14 or 21 mg)
Trial: 16236688
Drug: Fluvoxamine 200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluvoxamine 200 mg/day
Trial: 10425951
Drug: Ketorolac tromethamine
RxNorm normalized name: Ketorolac Tromethamine
DrugBank: Ketorolac (DB00465)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ketorolac tromethamine (10 mg p.o.)
Trial: 10425951
Drug: Acetaminophen codeine
RxNorm normalized name: acetaminophen / codeine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acetaminophen codeine (325 mg/15 mg p.o.)
Trial: 7498204
Drug: Propranolol (120
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propranolol (120 mg.day‐1 in twice divided doses)
Trial: 2405720
Drug: Oral tetrahydroaminoacridine
RxNorm normalized name: Tetrahydroaminoacridine
DrugBank: Tacrine (DB00382)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral tetrahydroaminoacridine (THA) and lecithin
Trial: 2405720
Drug: Long-term treatment
RxNorm normalized name: benzethonium
DrugBank: Benzethonium (DB11125)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Long-term treatment with THA and lecithin
Trial: 31821591
Drug: Efgartigimod 5
RxNorm normalized name: Efgartigimod alfa
DrugBank: Efgartigimod alfa (DB15270)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Efgartigimod 5 mg/kg
Trial: 24008684
Drug: Internet-based preparation
RxNorm normalized name: cranberry preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Internet-based preparation for inpatient psychosomatic psychotherapeutic treatment (VORSTAT)
Trial: 21458107
Drug: Enteric-coated mycophenolate
RxNorm normalized name: mycophenolic acid
DrugBank: Mycophenolic acid (DB01024)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Enteric-coated mycophenolate sodium (EC-MPS) 1440 mg
Trial: 11054648
Drug: IGF-I (80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IGF-I (80 microg/kg body weight, daily two s.c. injections for five days)
Trial: 9113634
Drug: HI20:4 diet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HI20:4 diet (1.7 g/d arachidonic acid)
Trial: 9113634
Drug: LO20:4 diet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LO20:4 diet (0.21 g/d arachidonic acid)
Trial: 3532439
Drug: Trazodone hydrochloride
RxNorm normalized name: Trazodone Hydrochloride
DrugBank: Trazodone (DB00656)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Trazodone hydrochloride 10 mg intravenously every 12 hours for seven days
Trial: 18498362
Drug: Two-implant overdenture
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two-implant overdenture (IOD)
Trial: 28426476
Drug: Intrasphincteric injections
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intrasphincteric injections of autologous myoblasts (AM)
Trial: 28426476
Drug: Delayed frozen
RxNorm normalized name: thrombin
DrugBank: Thrombin (DB11300)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Delayed frozen AM injection in placebo group
Trial: 22012130
Drug: High-dose recombinant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose recombinant human erythropoietin (rHuEPO) 40,000 units
Trial: 21118924
Drug: Monthly SP
RxNorm normalized name: SPS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Monthly SP
Trial: 21118924
Drug: AZI-SP (monthly
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AZI-SP (monthly SP and two doses of azithromycin)
Trial: 21118924
Drug: Controls (sulfadoxine‐pyrimethamine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Controls (sulfadoxine‐pyrimethamine twice)
Trial: 17541591
Drug: Vinorelbine 30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vinorelbine 30 mg/m2 i.v.
Trial: 17541591
Drug: Vinorelbine 80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vinorelbine 80 mg/m2 oral
Trial: 17541591
Drug: Both oral
RxNorm normalized name: Bothrops atrox venom
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both oral and i.v. forms
Trial: 9585289
Drug: Lidocaine plus
RxNorm normalized name: Icy Hot Lidocaine Plus Menthol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lidocaine plus 0.2 mg of epinephrine (Group B)
Trial: 9585289
Drug: Lidocaine plus
RxNorm normalized name: Icy Hot Lidocaine Plus Menthol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lidocaine plus 0.4 mg of epinephrine (Group C)
Trial: 9585289
Drug: Lidocaine plus
RxNorm normalized name: Icy Hot Lidocaine Plus Menthol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lidocaine plus 0.6 mg of epinephrine (Group D)
Trial: 7712756
Drug: Growth hormone
RxNorm normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Growth hormone (0.1 mg/kg/day)
Trial: 2667704
Drug: Topical lidocaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical lidocaine (52 mg/nasal cavity)
Trial: 827772
Drug: Physostigmine (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Physostigmine (3 mg total dose, intravenously)
Trial: 18613931
Drug: Simulation of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Simulation of an infusion of 1 mug.kg(‐1) over 10 min followed by an infusion of 0.7 mug.kg(‐1).h(‐1) for 50 min
Trial: 15760322
Drug: Weekly intramuscular
RxNorm normalized name: elagolix
DrugBank: Elagolix (DB11979)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Weekly intramuscular methotrexate at 30 mg/m(2)
Trial: 15760322
Drug: Intravenous dactinomycin
RxNorm normalized name: Dactinomycin
DrugBank: Dactinomycin (DB00970)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous dactinomycin at 1.25 mg/m(2) every 2 weeks
Trial: 10567783
Drug: Gemifloxacin 320
RxNorm normalized name: gemifloxacin 320 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gemifloxacin 320 mg o.d. for 7 days
Trial: 10567783
Drug: Ciprofloxacin 500
RxNorm normalized name: ciprofloxacin 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ciprofloxacin 500 mg b.d. for 7 days
Trial: 10567783
Drug: Gemifloxacin 160
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gemifloxacin 160 mg o.d. for 7 days
Trial: 387068
Drug: Ritodrine hydrochloride
RxNorm normalized name: Ritodrine Hydrochloride
DrugBank: Ritodrine (DB00867)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ritodrine hydrochloride 40 mg by mouth daily
Trial: 23944300
Drug: Faldaprevir 120
RxNorm normalized name: Faldaprévir
DrugBank: Faldaprevir (DB11808)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Faldaprevir 120 mg once daily and Deleobuvir 600 mg three times daily plus ribavirin for 16 weeks (TID16W)
Trial: 23944300
Drug: Faldaprevir 120
RxNorm normalized name: Faldaprévir
DrugBank: Faldaprevir (DB11808)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Faldaprevir 120 mg once daily and Deleobuvir 600 mg three times daily plus ribavirin for 28 weeks (TID28W)
Trial: 23944300
Drug: Faldaprevir 120
RxNorm normalized name: Faldaprévir
DrugBank: Faldaprevir (DB11808)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Faldaprevir 120 mg once daily and Deleobuvir 600 mg three times daily plus ribavirin for 40 weeks (TID40W)
Trial: 23944300
Drug: Faldaprevir 120
RxNorm normalized name: Faldaprévir
DrugBank: Faldaprevir (DB11808)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Faldaprevir 120 mg once daily and Deleobuvir 600 mg twice daily plus ribavirin for 28 weeks (BID28W)
Trial: 23944300
Drug: Faldaprevir 120
RxNorm normalized name: Faldaprévir
DrugBank: Faldaprevir (DB11808)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Faldaprevir 120 mg once daily and Deleobuvir 600 mg three times daily without ribavirin for 28 weeks (TID28W‐NR)
Trial: 9953
Drug: Intramuscular diamorphine
RxNorm normalized name: Diamorphine
DrugBank: Diamorphine (DB01452)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular diamorphine
Trial: 15291378
Drug: Olmesartan 10
RxNorm normalized name: amlodipine-olmesartan 10 mg-20 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Olmesartan 10 mg/d
Trial: 11997274
Drug: Vitamin E
RxNorm normalized name: Vitamin E
DrugBank: Vitamin E (DB00163)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Vitamin E (300 mg/d)
Trial: 2093382
Drug: Trimetazidine 60
RxNorm normalized name: trimetazidine
DrugBank: Trimetazidine (DB09069)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trimetazidine 60 mg per day
Trial: 24261811
Drug: Intranasal vaccination
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intranasal vaccination with a minimum immunizing dose of BRSV (experiment 1)
Trial: 24261811
Drug: Intranasal vaccination
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intranasal vaccination with a commercially available combination modified-live virus vaccine (experiments 2 and 3)
Trial: 24261811
Drug: Intranasal vaccination
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intranasal vaccination (experiments 1, 2, and 3)
Trial: 17551835
Drug: Bowman-Birk inhibitor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bowman-Birk inhibitor concentrate (BBIC) for 12 weeks
Trial: 17242499
Drug: Oral prednisone,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral prednisone, 40 mg/day for 7 days
Trial: 17242499
Drug: Intramuscular triamcinolone
RxNorm normalized name: Triamcinolone
DrugBank: Triamcinolone (DB00620)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intramuscular triamcinolone LA, 40 mg/day for 3 days
Trial: 12540390
Drug: L. helveticus
RxNorm normalized name: L. helveticus,rhamnosus/B. longum/zinc yeast/selenium yeast 2 billion cell-2 mg-12.5 mcg ORAL CAPSULE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L. helveticus LBK‐16H fermented milk (150 mL/d)
Trial: 8861533
Drug: Fleroxacin 400
RxNorm normalized name: fleroxacin 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fleroxacin 400 mg once daily intravenously for 2-4 days followed by oral doses of 400 mg for up to 10 days
Trial: 8861533
Drug: Ciprofloxacin 400
RxNorm normalized name: ciprofloxacin 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ciprofloxacin 400 mg twice daily intravenously for 2-4 days followed by oral doses of 2 x 500 mg for up to 10 days